January 25, 2024
Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial
Read moreOctober 19, 2023
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
Read moreMarch 6, 2023
Currax Files Lawsuit Against Found Health for False Marketing of Generic Equivalent of CONTRAVE®
Read moreAugust 30, 2022
One Size Does Not Fit All™: Currax Pharmaceuticals Launches New Campaign to Address Emotional Eating Challenges Faced by Individuals Seeking Weight Loss
Read moreJanuary 7, 2022
Currax Pharmaceuticals Appoints Michael Kyle, M.D., as Senior Vice President, Chief Medical Officer
Read moreOctober 26, 2021
Currax Pharmaceuticals Announces the Appointment of Ed Cinca to Senior Vice President, Global Marketing and Strategic Alliance Management
Read moreOctober 21, 2021
Currax Pharmaceuticals Granted Type C Meeting with FDA Regarding its Phase 3 Study to Evaluate the Safety and Efficacy of CX-101
Read moreSeptember 30, 2021
Currax Pharmaceuticals Hosted Ribbon-Cutting Ceremony to Mark the Opening of its Nashville Headquarters
Read moreAugust 2, 2021
Currax Pharmaceuticals Moves Global Headquarters to Brentwood, Tennessee
Read moreJune 25, 2021